Background Image
Previous Page  168 / 182 Next Page
Information
Show Menu
Previous Page 168 / 182 Next Page
Page Background

167

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

199

ONSOLIS (fentanyl buccal soluble film): US prescribing information. Somerset (NJ):

Meda Pharmaceuticals Ltd [online]. Verfügbar online über URL:

http://www.onsolis

.

com/pdf/onsolis_pi.pdf [aufgerufen am 31.10.2012].

200

Osenbach RK, Harvey S. Neuraxial infusion in patients with chronic intractable cancer

and noncancer pain. Current Pain and Headache Reports 2001; 5: 241-249.

201

Parlow JL, Milne B, Tod DA, Stewart GI, Griffiths JM, Dudgeon DJ. Self-administered

nitrous oxide for the management of incident pain in terminally ill patients: a blinded

case series. Palliative Medicine 2005; 19(1): 3-8.

202

Patt RB, Ellsion NM. Breakthrough pain in cancer patients: characteristics, prevalence

and treatment. Oncology (Huntington) 1998; 12: 1035-1052.

203

Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R, Berris R, Busch MA, Nordbrook

E, Loseth DB, Portenoy RK. Long-term safety of oral transmucosal fentanyl citrate for

breakthrough cancer pain. J Pain Symptom Manage. 2001; 22(1): 575-583.

204

Pease N, Taylor H, Major H. Driving advice for palliative care patients taking strong

opioid medication. Palliative Medicine 2004; 18: 663-665.

205

Petzke F, Radbruch L, Zech D, Loick G, Grond S. Temporal presentation of chronic cancer

pain: transitory pains on admission to a multidisciplinary pain clinic. Journal of Pain and

Symptom Management 1999; 17: 391-401.

206

Portenoy RK, Bennett DS, Rauck R, Simon S, Taylor D, Brennan M, Shoemaker S. Preva-

lence and characteristics of breakthrough pain in opioid-treated patients with chronic

noncancer pain. Journal of Pain 2006; 7(8): 583-591.

207

Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-

dwelling patients with cancer pain and noncancer pain, part 1: prevalence and charac-

teristics. J Opioid Manag 2010; 6(2): 97-108.

208

Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-

dwelling patients with cancer pain and noncancer pain, part 2: impact on function,

mood, and quality of life. J Opioid Manag 2010; 6(2): 109-116.

209

Portenoy RK, Burton AW, Gabrail N, Taylor D; Fentanyl Pectin Nasal Spray 043 Study

Group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of

Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain

2010; 151(3): 617-624.

210

Portenoy RK, Forbes K, Lussier D, Hanks G. Difficult pain problems: an integrated ap-

proach. In: Doyle D, Hanks G, Cherny N, Calman K, editors. Oxford Textbook of Palliative

Medicine. 3rd ed. Oxford: Oxford University Press; 2004. p. 438-458.

211

Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics.

Pain 1990; 41(3): 273-281.

212

Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of break-

through pain in opioid-treated patients with chronic low back pain: a randomized,

placebo-controlled study. Curr Med Res Opin 2007; 23(1): 223-233.

213

Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in

patients with cancer pain. Pain 1999; 81(1-2): 129-134.

Literaturverzeichnis